IPH6501

DRUG2 trials

Sponsors

Innate Pharma

Conditions

Non Hodgkin LymphomaRelapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

Phase 1

Phase1/2 Study of IPH6501 in Patients With Relapsed /Refractory B-Cell Non-Hodgkin Lymphoma

TerminatedNCT06088654

Innate PharmaNon Hodgkin Lymphoma

Start: 2024-03-04End: 2026-02-06Updated: 2026-04-14

A Phase 1/2, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of IPH6501 in Patients with Relapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

RecruitingCTIS2023-506976-28-00

Innate PharmaRelapsed and/or Refractory CD20-expressing Non-Hodgkin Lymphoma

Start: 2024-05-16Target: 25Updated: 2026-01-27

Related Papers

Preclinical Characterization of Antitumor Activity of IPH6501, a First-in-Class IL2v-Armed Tetraspecific NK Cell Engager Directed Against CD20, and Comparison with Approved CD20-Targeting Therapies

Blood2024-11-05

A phase 1/2, open-label, multicenter trial investigating the safety, tolerability, and preliminary antineoplastic activity of IPH6501, a first-in-class NK cell engager, in patients with relapsed and/or refractory CD20-expressing non-Hodgkin lymphoma.

Journal of Clinical Oncology2024-06-011 citations